RxSight, Inc.

Name: RxSight, Inc. standardized financial statements, quarterly
Creator: Listed

RXSTNasdaqCIK 1111485HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$27.2m, Q2 FY2026

Operating income−$13.8m, Q2 FY2026

Net income−$12.1m, Q2 FY2026

RxSight, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	22.2	28.6	29.5	34.9	35.3	40.2	37.9	33.6	30.3	32.6	30.9	27.2
Cost of revenue	$m	8.5	10.9	8.8	10.6	10.1	11.4	9.6	8.4	6.1	7.3	7.4	7.9
Gross profit	$m	13.7	17.7	20.7	24.3	25.2	28.8	28.3	25.2	24.2	25.3	23.5	not reported
Research and development	$m	7.1	7.3	8.0	8.3	8.8	9.2	10.4	10.2	9.1	8.9	9.5	9.2
Selling, general and administrative	$m	19.1	21.2	23.3	24.3	25.6	28.2	28.6	29.0	27.3	27.7	31.9	30.4
Operating income	$m	(12.5)	(10.9)	(10.7)	(8.3)	(9.2)	(8.6)	(10.7)	(14.0)	(12.2)	(11.3)	(17.8)	(13.8)
Interest expense	$m	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income tax	$m	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Net income	$m	(12.4)	(9.2)	(9.1)	(6.1)	(6.3)	(5.9)	(8.2)	(11.8)	(9.8)	(9.2)	(15.9)	(12.1)
Diluted EPS	$ per share	(0.35)	not reported	(0.25)	(0.16)	(0.16)	not reported	(0.20)	(0.29)	(0.24)	not reported	(0.38)	(0.29)
Basic EPS	$ per share	(0.35)	not reported	(0.25)	(0.16)	(0.16)	not reported	(0.20)	(0.29)	(0.24)	not reported	(0.38)	(0.29)

Balance sheet

Cash and equivalents$13.4m, Q2 FY2026

Long-term debt$0, FY2023

Shareholders' equity$263.3m, Q2 FY2026

RxSight, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	9.9	9.7	32.6	24.4	16.7	16.7	28.0	40.4	29.6	19.9	17.6	13.4
Current assets	$m	168	168	169	281	287	294	288	284	284	287	279	327
Total assets	$m	182	183	183	305	310	319	313	309	309	312	304	353
Current liabilities	$m	18.9	20.9	18.3	19.6	22.6	25.9	22.7	20.4	22.3	26.3	27.4	80.4
Total liabilities	$m	20.4	22.2	19.2	30.3	33.2	37.3	33.7	31.0	32.6	36.1	36.7	89.4
Long-term debt	$m	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	161	160	164	275	277	281	279	278	276	276	267	263

Cash flow

Operating cash flow−$9.5m, Q2 FY2026

Capital expenditure$2.0m, Q2 FY2026

RxSight, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(8.0)	(8.3)	(9.3)	(4.0)	0.7	(4.3)	(8.8)	(4.4)	(1.2)	(1.1)	(10.9)	(9.5)
Capital expenditure	$m	0.7	1.6	2.0	1.5	1.1	0.8	0.6	1.5	0.6	1.1	0.8	2.0

Diluted shares (weighted)41.49m, Q2 FY2026

RxSight, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	27.7	31.6	34.5	35.7	36.8	38.5	39.8	40.5	40.7	41.0	41.3	41.5

Shares outstanding: 41.59m at Jul 31, 2026, from the cover of the 10-Q filed Aug 5, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.